Pharmaceutical

Astellas and Evopoint sign ADC licensing deal

Astellas Pharma has signed an exclusive licensing agreement with Evopoint Biosciences for XNW27011, a CLDN18.2-targeting clinical-stage ADC.

Jun 1, 2025 - 06:00
Astellas and Evopoint sign ADC licensing deal
Astellas Pharma has signed an exclusive licensing agreement with Evopoint Biosciences for XNW27011, a CLDN18.2-targeting clinical-stage ADC.
Read the original article

Tags:

Previous Article

FDA rejects Stealth Bio’s Barth syndrome treatment after 16.5-month review

Next Article

Daiichi Sankyo and MSD withdraw US BLA for lung cancer treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA approves Vertex’s acute pain treatment Journavx

FDA approves Vertex’s acute pain treatment Journavx

Feb 1, 2025

STAT+: Biogen says it will cut costs by $700 million, slash 1,000 jobs

STAT+: Biogen says it will cut costs by $700 million, s...

Jul 26, 2023

STAT+: Pharmalittle: Lilly expects Medicare to back down on Alzheimer’s drug coverage; key senators change insulin cap proposal

STAT+: Pharmalittle: Lilly expects Medicare to back dow...

Apr 21, 2023